接受基于抗血管生成疗法的癌症患者的高血压问题。
Hypertension in cancer patients treated with anti-angiogenic based regimens.
作者信息
Wasserstrum Yishay, Kornowski Ran, Raanani Pia, Leader Avi, Pasvolsky Oren, Iakobishvili Zaza
机构信息
Department of Cardiology, Rabin Medical Center, Petah Tikva, 49100, Israel.
Sackler School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
出版信息
Cardiooncology. 2015 Dec 7;1(1):6. doi: 10.1186/s40959-015-0009-4.
Abstract
New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular safety. The most common side effect of VEGF signaling pathway (VSP) inhibition is the development of systemic hypertension. We review the incidence, possible mechanisms, significance and management of hypertension in patients treated with VSP inhibitors.
摘要
抑制血管内皮生长因子（VEGF）信号通路的新型抗癌药物在实体瘤治疗中疗效显著，但人们仍对其心血管安全性有所担忧。VEGF信号通路（VSP）抑制最常见的副作用是全身性高血压。我们综述了接受VSP抑制剂治疗患者高血压的发生率、可能机制、意义及管理。
相似文献
1
Hypertension in cancer patients treated with anti-angiogenic based regimens.接受基于抗血管生成疗法的癌症患者的高血压问题。
Cardiooncology. 2015 Dec 7;1(1):6. doi: 10.1186/s40959-015-0009-4.
2
Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.认识并处理与血管内皮生长因子信号通路治疗性抑制相关的左心室功能障碍。
Curr Treat Options Cardiovasc Med. 2014 Sep;16(9):335. doi: 10.1007/s11936-014-0335-0.
3
Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events.血管内皮生长因子（VEGF）抑制剂疗法的血管毒性——聚焦于高血压和动脉血栓形成事件。
J Am Soc Hypertens. 2018 Jun;12(6):409-425. doi: 10.1016/j.jash.2018.03.008. Epub 2018 Mar 21.
4
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.血管内皮生长因子抑制剂治疗相关的心脏毒性
NPJ Precis Oncol. 2018 May 8;2:13. doi: 10.1038/s41698-018-0056-z. eCollection 2018.
5
Both New-Onset and Pre-Existing Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy.接受抗血管内皮生长因子治疗的患者中，新发和已有的高血压均表明有利的临床结局。
Circ J. 2024 Jan 25;88(2):217-225. doi: 10.1253/circj.CJ-22-0628. Epub 2022 Dec 6.
6
Tyrosine Kinase Inhibitor-Induced Hypertension.酪氨酸激酶抑制剂相关性高血压。
Curr Oncol Rep. 2018 Jun 21;20(8):65. doi: 10.1007/s11912-018-0708-8.
7
Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.实体癌中的抗血管生成药物、血管毒性与血栓栓塞
Cardiovasc Hematol Agents Med Chem. 2017;15(1):3-16. doi: 10.2174/1871525715666170127101605.
8
Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.抗血管内皮生长因子/血管内皮生长因子受体药物对血管生成血管的早期作用。
Am J Pathol. 2017 Oct;187(10):2337-2347. doi: 10.1016/j.ajpath.2017.06.010. Epub 2017 Jul 21.
9
Acute blood pressure elevation associated with biological therapies for cancer: a focus on VEGF signaling pathway inhibitors.癌症生物治疗相关的急性血压升高：以 VEGF 信号通路抑制剂为重点。
Expert Opin Biol Ther. 2019 May;19(5):433-442. doi: 10.1080/14712598.2019.1594770. Epub 2019 Apr 8.
10
Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors.血管内皮生长因子抑制剂所致的心血管毒性
Life (Basel). 2023 Jan 29;13(2):366. doi: 10.3390/life13020366.
引用本文的文献
1
Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice.乐伐替尼在放射性碘难治性分化型甲状腺癌治疗中的应用：日常实践中的多学科视角。
Eur Thyroid J. 2023 Aug 8;12(5):e230068. doi: 10.1530/ETJ-23-0068.
2
Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.分析转移性肾细胞癌患者应用血管内皮生长因子受体-酪氨酸激酶抑制剂（VEGFR-TKIs）相关抗血管生成不良反应。
Target Oncol. 2023 Mar;18(2):247-255. doi: 10.1007/s11523-023-00951-z. Epub 2023 Feb 24.
3
Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory-differentiated thyroid cancer.多激酶抑制剂/仑伐替尼在心血管高危/血管病变和放射性碘难治性分化型甲状腺癌患者中的应用。
Cancer Med. 2022 Oct;11 Suppl 1(Suppl 1):17-25. doi: 10.1002/cam4.5127.
4
Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity.介导酪氨酸激酶抑制剂心脏毒性的细胞内信号通路。
Heart Fail Clin. 2022 Jul;18(3):425-442. doi: 10.1016/j.hfc.2022.02.003. Epub 2022 Jun 1.
5
Incidence and risk factors of hypertension therapy in Australian cancer patients treated with vascular signalling pathway inhibitors.澳大利亚接受血管信号通路抑制剂治疗的癌症患者中高血压治疗的发生率及危险因素。
Discov Oncol. 2022 Jan 20;13(1):6. doi: 10.1007/s12672-022-00468-3.
6
Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats.环氧二十碳三烯酸类似物与20-羟基二十碳四烯酸拮抗剂联合用药可预防自发性高血压大鼠发生高血压。
Front Pharmacol. 2022 Jan 17;12:798642. doi: 10.3389/fphar.2021.798642. eCollection 2021.
7
Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer-Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension.碘难治性分化型甲状腺癌的激酶抑制剂——聚焦于治疗相关高血压的发生、机制和管理。
Int J Mol Sci. 2021 Nov 12;22(22):12217. doi: 10.3390/ijms222212217.
8
Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor.靶向血管内皮生长因子的酪氨酸激酶抑制剂与血压升高相关。
JACC CardioOncol. 2019 Sep 24;1(1):24-36. doi: 10.1016/j.jaccao.2019.08.012. eCollection 2019 Sep.
9
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.雷莫芦单抗或安慰剂联合厄洛替尼治疗 EGFR 突变、转移性非小细胞肺癌：RELAY 的东亚亚组。
Cancer Sci. 2020 Dec;111(12):4510-4525. doi: 10.1111/cas.14655. Epub 2020 Oct 14.
10
Cardiovascular assessment after treatment for retinopathy of prematurity: a comparative study between anti-VEGF agent (aflibercept) and laser.早产儿视网膜病变治疗后的心血管评估：抗血管内皮生长因子药物（阿柏西普）与激光治疗的比较研究
Cardiovasc J Afr. 2020;31(3):123-129. doi: 10.5830/CVJA-2019-058. Epub 2020 Jan 13.
本文引用的文献
1
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.舒尼替尼相关的高血压和中性粒细胞减少作为转移性肾细胞癌患者疗效生物标志物
Br J Cancer. 2015 Dec 1;113(11):1571-80. doi: 10.1038/bjc.2015.368. Epub 2015 Oct 22.
2
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.高血压（HTN）作为晚期非脂肪性软组织肉瘤患者接受帕唑帕尼治疗的疗效潜在生物标志物：基于欧洲癌症研究与治疗组织（EORTC）62043 和 62072 试验的回顾性研究。
Eur J Cancer. 2015 Nov;51(17):2615-23. doi: 10.1016/j.ejca.2015.08.002. Epub 2015 Aug 25.
3
Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.血管紧张素系统抑制剂与转移性肾细胞癌患者的生存结局
Clin Cancer Res. 2015 Jun 1;21(11):2471-9. doi: 10.1158/1078-0432.CCR-14-2332. Epub 2015 Feb 27.
4
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.一项将MEK1/MEK2抑制剂曲美替尼（GSK1120212）与多西他赛对比用于KRAS突变的晚期非小细胞肺癌（NSCLC）的随机II期研究†。
Ann Oncol. 2015 May;26(5):894-901. doi: 10.1093/annonc/mdv072. Epub 2015 Feb 26.
5
Large artery stiffness and hypertension after antiangiogenic drugs: influence on cancer progression.抗血管生成药物治疗后的大动脉僵硬度与高血压：对癌症进展的影响。
J Hypertens. 2015 Jun;33(6):1310-7. doi: 10.1097/HJH.0000000000000550.
6
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.乐伐替尼对比安慰剂用于碘难治性甲状腺癌。
N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470.
7
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.二线阿昔替尼治疗既往抗血管生成治疗后晚期肝细胞癌的 II 期临床试验。
Cancer. 2015 May 15;121(10):1620-7. doi: 10.1002/cncr.29227. Epub 2015 Jan 6.
8
Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.舒尼替尼引起的高血压、中性粒细胞减少和血小板减少作为转移性肾细胞癌患者预后良好的预测指标。
BJU Int. 2016 Jan;117(1):110-7. doi: 10.1111/bju.12940. Epub 2015 Jun 2.
9
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.接受VEGF信号通路抑制剂治疗的患者发生高血压的临床危险因素。
Cancer. 2015 Jan 15;121(2):311-9. doi: 10.1002/cncr.28972. Epub 2014 Sep 18.
10
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.卡博替尼用于化疗预处理的转移性去势抵抗性前列腺癌：一项II期非随机扩展研究的结果
J Clin Oncol. 2014 Oct 20;32(30):3391-9. doi: 10.1200/JCO.2013.54.5954. Epub 2014 Sep 15.
Zotero 插件